XTRA:BAYNPharmaceuticals
Bayer Stroke Trial Success Puts Asundexian And Valuation In Focus
Bayer reported positive topline results from its pivotal Phase III OCEANIC-STROKE trial for asundexian, a Factor XIa inhibitor for secondary stroke prevention.
The study showed a significant reduction in recurrent ischemic strokes versus placebo, without an increase in major bleeding events.
The data mark the first successful Phase III readout for a Factor XIa inhibitor showing superiority to placebo in this setting, and follow Fast Track designation for asundexian from the FDA.
Bayer,...